The specific financial interests of the co-authors, according to the anti-smoking groups are:

To add icing to the cake, Medical News Today that: "researchers from this latest study say thirdhand smoke is left on surfaces and ages over time, becoming increasingly more toxic. The team suggests second and thirdhand smoke are just as harmful as firsthand smoke."

Dr. Benowitz: "Dr. Benowitz, as a paid consultant for pharmaceutical companies, has assisted them with the design, development, and marketing of smoking-cessation products. Among the companies for which he has consulted on such products are GlaxoSmithKline plc and its affiliates (collectively, “GSK”); Pfizer, Inc. and its affiliates (collectively, “Pfizer”); Novartis AG and its affiliates (collectively, “Novartis”); Sanofi-Aventis U.S. LLC and its affiliates (collectively, “Sanofi-Aventis”); and Aradigm Corp. and its affiliates (collectively, “Aradigm”). During the last ten years, he has received at least approximately $10,000 per year for such consulting. He has also received grant support for research and writing from GSK and/or Pfizer on at least five occasions. In 2010, he co-authored a study, funded by Pfizer, on the use of its drug, Chantix, for smoking cessation."

LAST：newest products transparent 1.6ml ce4 ce4+ clearomizer/atomizer |NEXT：full mechanical FBT uptown clone mod ecig FBT mod